Global Hepatitis Drugs Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023

Description: Overview: Hepatitis is a medical condition where the liver is predominantly affected, which can also affect the digestive system and brain. There are three major types of hepatitis condition - HAV, HBV, and HCV. HCV is a major public health problem that attacks the liver and leads to inflammation. Certain drugs, toxins, heavy alcohol use, bacterial and viral infections can cause hepatitis infection. Hepatitis C infection can bring both acute and chronic hepatitis disease. Approximately, 80% of the patients get chronically infected with Hepatitis C disease. Hepatitis C Virus (HCV) spreads through the blood of an infected individual by the use of shared needles or supplies used to infuse drugs. Vaccines are available only for Hepatitis A and Hepatitis B viruses. Research into the development of a vaccine for Hepatitis C is under way.

Factors such as rise in injection drug users, increase in awareness, presence of unmet need, and anticipated launch of new drugs are expected to drive the market growth during the forecast period. The market is witnessing the emerging trend of pediatric combination vaccines, which protect against multiple causative agents and thereby reduce the costs gain in packaging and administering individual vaccines. The markets in India, Brazil, China, and Russia are also expected to grow at a rapid pace during the forecast period as the prevalence of hepatitis in these countries is high.

The major drivers of the hepatitis drugs market include the second generation DAAs of Olysio and Sovaldi. Second generation DAAs are more efficacious and have lesser adverse effects. Currently, the market players are developing IFN therapies for the treatment of Hepatitis C. These therapies are intended to be all-oral regimens. The HCV drugs segment comprised more than 84% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the hepatitis drugs market in the future.

Market Analysis: The “Global Hepatitis Drugs Market” is estimated to witness a CAGR of 15.0% during the forecast period 2017–2023. The Hepatitis Drugs market is analyzed based on two segments – conditions and regions.

Regional Analysis: The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the hepatitis drugs market growth followed by Europe. The Asia Pacific and RoW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various HBV and HCV drugs are expected to increase in the coming years.

Therapeutic Application Analysis: The most common hepatitis being viral hepatitis can be caused by either of the five hepatotropic viruses, namely Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, and Hepatitis E. The non-viral hepatitis can be caused by autoimmune diseases, alcohol, few of prescription medications, and toxic substances. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future HBV and HCV drugs to be commercially available in the market. The advent of interferon-free combination regimens and DAAs is one of the major drivers for the global hepatitis drugs market, specifically for the HCV market. Moreover, various IFN-regimens are under development as all-oral regimens. These therapies are expected to attain higher SVR and cause lesser side effects than currently approved therapies. The market is also witnessing various mergers, acquisitions, and collaborations among the top players, which is defining the future of the Global Hepatitis Drugs market.


Competitive Analysis: At present, the HCV drugs are dominating the Global Hepatitis Drugs market – but, a lot of new players are focusing on developing HBV drug molecules to gain future business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of hepatitis molecules and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.

Benefits: The report provides complete details about the usage and adoption rate of hepatitis drugs in
various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards the hepatitis drugs adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Contents:
1 Industry Outlook
  1.1 Industry Overview
  1.2 Industry Trends
  1.3 Pest Analysis

2 Report Outline
  2.1 Report Scope
  2.2 Report Summary
  2.3 Research Methodology
  2.4 Report Assumptions

3 Market Snapshot
  3.1 Total Addressable Market (TAM)
  3.2 Disease Overview
    3.2.1 Hepatitis A
      3.2.1.1 Epidemiology
      3.2.1.2 Therapy
    3.2.2 Hepatitis B
      3.2.2.1 Epidemiology
      3.2.2.2 Therapy
    3.2.3 Hepatitis C
      3.2.3.1 Epidemiology
      3.2.3.2 Therapy
    3.2.4 Hepatitis D
    3.2.5 Hepatitis E
  3.3 Disease Transmission
  3.4 Related Markets

4 Market Outlook
  4.1 Overview
  4.2 Regulatory Bodies & Standards
  4.3 Porter 5 (Five) Forces

5 Market Characteristics
  5.1 Evolution
  5.2 ROADMAP
  5.3 Market Dynamics
    5.3.1 Drivers
      5.3.1.1 Increasing Demand of Hepatitis Drugs
      5.3.1.2 Focus on Advanced DAAs
      5.3.1.3 Introduction of IFN-free Therapies
      5.3.1.4 Growth of Injection Drug Users
      5.3.2 Restraints
      5.3.2.1 Long Approval Process and Stringent Regulations
      5.3.2.2 Side Effects of Hepatitis Drugs
      5.3.2.3 Increase in the Number of Generic Drugs
      5.3.2.4 Increasing Market Competition
      5.3.3 Opportunities
        5.3.3.1 Significant Increase in Mergers and Acquisitions
        5.3.3.2 Emergence of Combination Drugs
        5.3.3.3 Preventive Healthcare
        5.3.3.4 Focus of Companies on Emerging Market
    5.3.4 DRO - Impact Analysis
6 Trends, Roadmap and Projects
6.1 Market Trends & Impact
6.2 Technology Roadmap

7 Types: Market Size & Analysis
7.1 Overview
7.2 Hepatitis A Segment
7.3 Hepatitis B Segment
7.4 Hepatitis C Segment

8 Trending Hepatitis Drugs
8.1 Overview
8.1.1 VEMLIDY
8.1.2 EPCLUSA
8.1.3 SOVALDI
8.1.4 INCIVEK
8.1.5 OLYSIO
8.1.6 VICTRELIS
8.1.7 VIREAD
8.1.8 HEPSERA
8.1.9 BARA CLUDE
8.1.10 TYZEKA
8.1.11 INTRON A
8.1.12 PEGASYS
8.1.13 PEGINTRON
8.1.14 ROFERON-A
8.1.15 VIRA FERONPEG
8.1.16 REBETOL

9 Regions: Market Size & Analysis
9.1 OVERVIEW
9.1.1.1 Global Hepatitis Drugs Market by Geographical Segmentation

10 Vendor Scenario
10.1 Market Share Ranking 2016
10.1.1 GILEAD SCIENCES INC.
10.1.1.1 Sovaldi (sofosbuvir)
10.1.1.2 Harvoni (ledipasvir and sofosbuvir)
10.1.1.3 Viread (tenofovir disoproxil fumarate)
10.1.1.4 Hepsera (adefovir dipivoxil)
10.1.2 ABBVIE INC.
10.1.2.1 Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir)
10.1.3 JOHNSON & JOHNSON
10.1.3.1 Olysio (simeprevir)
10.1.3.2 Incivo (telaprevir)
10.1.4 MERCK & CO. INC.
10.1.4.1 Zepatier (elbasvir and grazoprevir)
10.1.4.2 Victrelis (boceprevir)
10.1.4.3 Peg-Intron (peginterferon alfa-2b)
10.1.4.4 Rebetol (ribavirin)
10.1.4.5 Intron A (interferon alfa-2b, recombinant)
10.1.5 GLAXOSMITHKLINE PLC
10.1.5.1 Pediarix Vaccine
10.1.5.2 Twinrix
10.1.5.3 Havrix
10.1.5.4 Epivir (lamivudine)
10.1.6 VERTEX PHARMACEUTICALS INC.
10.1.6.1 Incivek (telaprevir)
10.1.7 NOVARTIS AG
10.1.7.1 Tyzeka (telbivudine)
10.1.8 HOFFMANN-LA ROCHE LTD.
10.1.8.1 Pegasys (peginterferon alfa-2a)
11 Vendor Profiles
11.1.1 Merck & Co. Inc.
11.1.1.1 Overview
11.1.1.2 Business unit
11.1.1.3 Geographic revenue
11.1.1.4 Recent developments
11.1.1.5 SWOT analysis
11.1.1.6 Business strategies
11.1.2 Hoffmann-La Roche Ltd.
11.1.2.1 Overview
11.1.2.2 Business Unit
11.1.2.3 Geographic revenue
11.1.2.4 Recent developments
11.1.2.5 SWOT analysis
11.1.2.6 Business strategies
11.1.3 Gilead Sciences
11.1.3.1 Overview
11.1.3.2 Business Unit
11.1.3.3 Geographic revenue
11.1.3.4 Recent developments
11.1.3.5 SWOT analysis
11.1.3.6 Business strategies
11.1.4 Novartis AG
11.1.4.1 Overview
11.1.4.2 Business Unit
11.1.4.3 Geographic revenue
11.1.4.4 Recent developments
11.1.4.5 SWOT analysis
11.1.4.6 Business strategies
11.1.5 GlaxoSmithKline plc
11.1.5.1 Overview
11.1.5.2 Business Unit
11.1.5.3 Geographic revenue
11.1.5.4 Recent developments
11.1.5.5 SWOT analysis
11.1.5.6 Business strategies

12 Global Generalist
12.1 Vertex Pharmaceuticals Inc.
12.1.1 Overview
12.1.1.1 Recent developments
12.1.2 Vertex Pharmaceuticals Inc. in 2015
12.2 Johnson & Johnson
12.2.1 Overview
12.2.1.1 Recent developments
12.2.2 Johnson & Johnson in 2015

13 Market Landscape
13.1 Market Landscape
13.1.1 Mergers & Acquisitions (M&A)
Annexure
Acronyms

Ordering: Order Online - http://www.researchandmarkets.com/reports/4092020/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Global Hepatitis Drugs Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/4092020/">http://www.researchandmarkets.com/reports/4092020/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC2GZD3Q</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Electronic (PDF) - Single User: USD 2500</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Electronic (PDF) - Site License: USD 2750</td>
</tr>
<tr>
<td></td>
<td>Electronic (PDF) - Enterprisewide: USD 3500</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>__________________________________</td>
</tr>
<tr>
<td>Last Name:</td>
<td>__________________________________</td>
</tr>
<tr>
<td>Email Address: *</td>
<td>__________________________________</td>
</tr>
<tr>
<td>Job Title:</td>
<td>__________________________________</td>
</tr>
<tr>
<td>Organisation:</td>
<td>__________________________________</td>
</tr>
<tr>
<td>Address:</td>
<td>__________________________________</td>
</tr>
<tr>
<td>City:</td>
<td>__________________________________</td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>__________________________________</td>
</tr>
<tr>
<td>Country:</td>
<td>__________________________________</td>
</tr>
<tr>
<td>Phone Number:</td>
<td>__________________________________</td>
</tr>
<tr>
<td>Fax Number:</td>
<td>__________________________________</td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World